摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2,3-Dihydroxy-1-methyl-naphthalin | 1991-33-9

中文名称
——
中文别名
——
英文名称
2,3-Dihydroxy-1-methyl-naphthalin
英文别名
1-methyl-naphthalene-2,3-diol;1-Methyl-naphthalin-2,3-diol;1-methyl-2,3-dihydroxy-naphthalene;1-methylnaphthalene-2,3-diol
2,3-Dihydroxy-1-methyl-naphthalin化学式
CAS
1991-33-9
化学式
C11H10O2
mdl
——
分子量
174.199
InChiKey
GDYAUGXOIOIFLD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.8
  • 重原子数:
    13
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.09
  • 拓扑面积:
    40.5
  • 氢给体数:
    2
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Imidazole derivatives
    申请人:Hoffmann-La Roche Inc.
    公开号:US04435406A1
    公开(公告)日:1984-03-06
    Tricyclic imidazole derivatives of the formula ##STR1## wherein R.sup.1 is 2-pyridyl optionally substituted by lower alkyl or lower alkoxy, n is the integer 0 or 1, R.sup.2 is hydrogen or lower alkyl, R.sup.3 and R.sup.4, independently, are hydrogen or lower alkyl, A is a group of the formula ##STR2## m is the integer 2 or 3, R.sup.5, R.sup.6, R.sup.7 and R.sup.8, independently, are hydrogen or lower alkyl, and R.sup.9 is hydrogen and R.sup.10 is hydrogen or lower alkyl or R.sup.9 and R.sup.10 taken together are oxo, provided that at least one of R.sup.3 and R.sup.4 is lower alkyl when A is a group of the formula --CH.dbd.CH--CH.dbd.CH-- or --(CH.sub.2).sub.4 --, and their pharmaceutically acceptable acid addition salts. The compounds of formula I inhibit gastric acid secretion and prevent the formation of gastric ulcers.
    Tricyclic imidazole derivatives of the formula ##STR1## wherein R.sup.1 is 2-pyridyl optionally substituted by lower alkyl or lower alkoxy, n is the integer 0 or 1, R.sup.2 is hydrogen or lower alkyl, R.sup.3 and R.sup.4, independently, are hydrogen or lower alkyl, A is a group of the formula ##STR2## m is the integer 2 or 3, R.sup.5, R.sup.6, R.sup.7 and R.sup.8, independently, are hydrogen or lower alkyl, and R.sup.9 is hydrogen and R.sup.10 is hydrogen or lower alkyl or R.sup.9 and R.sup.10 taken together are oxo, provided that at least one of R.sup.3 and R.sup.4 is lower alkyl when A is a group of the formula --CH.dbd.CH--CH.dbd.CH-- or --(CH.sub.2).sub.4 --, and their pharmaceutically acceptable acid addition salts. The compounds of formula I inhibit gastric acid secretion and prevent the formation of gastric ulcers.
  • Method for producing allyl compound, and ether or ester compound produced thereby
    申请人:MITSUBISHI CHEMICAL CORPORATION
    公开号:US20040147757A1
    公开(公告)日:2004-07-29
    A method for producing an allyl compound having a compositional formula different from that of an allyl starting material compound, which comprises reacting the allyl starting material compound with an oxygen nucleophilic agent in the presence of a catalyst containing at least one transition metal compound containing a transition metal selected from the group consisting of transition metals belonging to Group 8 to Group 10 of the Periodic Table and a multidentate phosphite compound.
    一种生产具有与烯丙基起始物质化合物不同的组成式的烯丙基化合物的方法,包括在存在至少一种含有从周期表第8组到第10组的过渡金属属于的过渡金属的过渡金属化合物和多齿膦酸酯化合物的催化剂的情况下,将烯丙基起始物质化合物与氧亲核试剂反应。
  • Method for producing allyl compound
    申请人:MITSUBISHI CHEMICAL CORPORATION
    公开号:US20040092777A1
    公开(公告)日:2004-05-13
    A method for producing an allyl compound having a compositional formula different from that of an allyl starting material compound, which comprises reacting the allyl starting material compound with an oxygen nucleophilic agent having a structure different from that of the allyl starting material compound in the presence of a catalyst containing at least one transition metal compound containing a transition metal selected from the group consisting of transition metals belonging to Group 8 to Group 10 of the Periodic Table and a monodentate phosphite compound having a structure of the following formula (1): P(OR 1 )(OR 2 )(OR 3 )   (1) wherein R 1 , R 2 and R 3 are respectively independently an alkyl group which may have a substituent, carbon chains of R 1 , R 2 and R 3 may have at least one carbon-carbon double bond or triple bond, and at least two optional groups of R 1 , R 2 and R 3 may bond to each other to form at least one cyclic structure.
    一种制备具有与烯丙基起始材料化合物不同组成式的烯丙基化合物的方法,包括在至少包含选择自周期表8至10族过渡金属的过渡金属化合物和具有以下式(1)结构的单齿磷酸酯化合物催化剂存在下,将烯丙基起始材料化合物与具有不同于烯丙基起始材料化合物的结构的氧亲核试剂反应,其中式(1)中,R1、R2和R3分别独立地是可以具有取代基的烷基,R1、R2和R3的碳链可以具有至少一个碳-碳双键或三键,并且R1、R2和R3的至少两个可选基团可以结合形成至少一个环状结构。
  • Pyridyl methyl thio or sulfinyl indeno(5,6-d)imidazoles
    申请人:Hoffmann-La Roche Inc.
    公开号:US04554280A1
    公开(公告)日:1985-11-19
    Tricyclic imidazole derivatives of the formula ##STR1## wherein R.sup.1 is 2-pyridyl optionally substituted by lower alkyl or lower alkoxy, n is the integer 0 or 1, R.sup.2 is hydrogen or lower alkyl, R.sup.3 and R.sup.4, independently, are hydrogen or lower alkyl, A is a group of the formula ##STR2## m is the integer 2 or 3, R.sup.5, R.sup.6, R.sup.7 and R.sup.8, independently, are hydrogen or lower alkyl, and R.sup.9 is hydrogen and R.sup.10 is hydrogen or lower alkyl or R.sup.9 and R.sup.10 taken together are oxo, provided that at least one of R.sup.3 and R.sup.4 is lower alkyl when A is a group of the formula --CH.dbd.CH--CH.dbd.CH-- or --(CH.sub.2).sub.4 --, and their pharmaceutically acceptable acid addition salts. The compounds of formula I inhibit gastric acid secretion and prevent the formation of gastric ulcers.
    公式为 ##STR1## 的三环咪唑衍生物,其中R.sup.1是2-吡啶基,可选择地被低烷基或低烷氧基取代,n是整数0或1,R.sup.2是氢或低烷基,R.sup.3和R.sup.4独立地是氢或低烷基,A是公式 ##STR2## 的基团,m是整数2或3,R.sup.5,R.sup.6,R.sup.7和R.sup.8独立地是氢或低烷基,R.sup.9是氢,R.sup.10是氢或低烷基或R.sup.9和R.sup.10一起是氧代,但当A是公式--CH.dbd.CH--CH.dbd.CH--或--(CH.sub.2).sub.4--的基团时,至少R.sup.3和R.sup.4中的一个是低烷基,它们的药学上可接受的酸盐。公式I的化合物抑制胃酸分泌并预防胃溃疡的形成。
  • Method for producing allyl compound, and allyl compound produced thereby
    申请人:Takai Masaki
    公开号:US20050075518A1
    公开(公告)日:2005-04-07
    A method for producing an allyl compound having a compositional formula different from that of an allyl starting material compound, which comprises reacting the allyl starting material compound with a nucleophilic agent in the presence of a catalyst containing at least one transitional metal compound containing a transition metal selected from the group consisting of transition metals belonging to Group 8 to Group 10 of the Periodic Table and at least one bidentate coordinated phosphite compound selected from the group consisting of compounds having structures of the following formulae (I) to (III): wherein A 1 to A 3 are respectively independently a diarylene group having a branched alkyl group at the ortho-position, R 1 to R 6 are respectively independently an alkyl group which may have a substituent or an aryl group which may have a substituent (including a heterocyclic compound forming an aromatic 6π electron cloud on the upper and lower sides of the ring, hereinafter the same), and Z 1 to Z 3 are respectively independently an alkylene group which may have a substituent, an arylene group which may have a substituent, an alkylene-arylene group which may have a substituent or a diarylene group which may have a substituent.
    一种制备具有不同于烯丙基起始材料化合物的组成式的烯丙基化合物的方法,包括在催化剂的存在下,将烯丙基起始材料化合物与亲核试剂反应,所述催化剂包含至少一种过渡金属化合物,所述过渡金属选自周期表8到10组的过渡金属,并且至少一种双齿配位膦酸酯化合物,所述化合物具有以下式(I)到(III)中的结构,其中A1到A3分别独立地是具有支链烷基的二芳基基团,R1到R6分别独立地是可以具有取代基的烷基基团或可以具有取代基的芳基基团(包括在环上形成芳香6π电子云的杂环化合物,在此以后相同),Z1到Z3分别独立地是可以具有取代基的烷基,可以具有取代基的芳基,可以具有取代基的烷基-芳基基团或可以具有取代基的二芳基基团。
查看更多